GeneDx Announces Industry-Leading Accomplishment of 500,000 Clinical Exomes Sequenced
06 September 2023 - 10:00PM
GeneDx, a leader in delivering improved health outcomes through
genomic and clinical insights, today announced a monumental
accomplishment in its ongoing commitment to deliver personalized
and actionable health insights to inform diagnosis, direct
treatment and improve drug discovery. The company has successfully
sequenced more than 500,000 clinical exomes, solidifying its place
as an industry leader in exome sequencing, enhancing the robustness
of its proprietary dataset in order to enable more definitive
diagnoses for more patients.
“The path to 500,000 exomes is paved with the stories of
patients and their families in search of answers, and the
unwavering dedication of their clinicians and our own team working
together to provide them,” said Katherine Stueland, President and
CEO, GeneDx. “Each exome stands as a testament to trust and
resilience of those who depend on us for answers, and with each
exome we run, our interpretation platform is improved for the next
patient, essentially paying it forward. Our deepest gratitude goes
out to all who have chosen us as partners to change the narrative
on genetic testing and to ultimately help end the diagnostic
odyssey for the families who desperately need answers.”
GeneDx pioneered whole exome sequencing in December 2012, and in
the last 18 months alone has sequenced more than a third of the
half million exomes. These test results, and corresponding clinical
data, including patient phenotypes, has enabled the company to
build one of the largest and most sophisticated proprietary genomic
datasets, enabling delivery of more definitive answers and
clinically actionable results faster. Today, GeneDx is proud to
have more than 80% exome market share among ordering
clinicians1.
“This milestone represents a huge win for patients. Exome
sequencing improves diagnostic rates, and in many cases, reduces
the financial burden incurred by families who are on a multi-year
diagnostic odyssey,” said Paul Kruszka, Chief Medical Officer. “We
continue to see expanding industry guidelines, and increased payor
coverage, which shows the momentum in improving access to testing.
However, we know there is still a lot of work to do to ensure all
patients who can benefit have access."
To find out more about GeneDx’s industry leading exome testing
visit www.genedx.com.
About GeneDx GeneDx (Nasdaq: WGS) delivers
personalized and actionable health insights to inform diagnosis,
direct treatment and improve drug discovery. The company is
uniquely positioned to accelerate the use of genomic and
large-scale clinical information to enable precision medicine as
the standard of care. GeneDx is at the forefront of transforming
healthcare through its industry-leading exome and genome testing
and interpretation, fueled by one of the world’s largest, rare
disease data sets. For more information, please
visit www.genedx.com and connect with us on LinkedIn, Facebook,
Twitter and Instagram.
GeneDx Investor Relations Contact: Tricia
Truehart Investors@GeneDx.com
GeneDx Media Contact: Teca
Lewellyn Press@GeneDx.com
References1 Based on Definitive Healthcare commercial claims
data (2023 through July) for CPT codes 81415, 81416 for clinicians
specializing in pediatric medicine & developmental
pediatrics
GeneDx (NASDAQ:WGS)
Historical Stock Chart
From Apr 2024 to May 2024
GeneDx (NASDAQ:WGS)
Historical Stock Chart
From May 2023 to May 2024